Alerts
GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?
A meta-analysis presented at the International Congress on Obesity found that GLP-1 medicines reduced weight and improved some cardiometabolic and quality-of-life measures in young people with obesity but without diabetes. The results are encouraging, particularly for adolescents aged 12 and older. Yet most trials lasted little more than a year, nausea was substantially more common,…
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
Regulators Start Writing the Rules for AI-Driven Medicines
FDA Puts AI Inside the Evidence Machine
AI Diagnosis Has Entered the Access Debate
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s AMR Plan Turns Access Into Preparedness
Geographic Atrophy Forces Europe to Define Meaningful Vision Benefit
Eye Health Moves From Charity Case to Investment Case
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.